Use of hepatitis B surface antigen-positive grafts in liver transplantation: A matched analysis of the US National database

Liver Transplantation

Volumn 20, Issue 1, 2014, Pages 35-45

  Li, Zhiwei ^a   Hu, Zhenhua ^a   Xiang, Jie ^a   Zhou, Jie ^a   Yan, Sheng ^a   Wu, Jian ^a   Zhou, Lin ^a   Zheng, Shusen ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

ADOLESCENT; ADULT; COHORT STUDIES; DATABASES, FACTUAL; END STAGE LIVER DISEASE; FEMALE; GRAFT SURVIVAL; HEPATITIS B SURFACE ANTIGENS; HUMANS; LIVER; LIVER TRANSPLANTATION; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES; WARM ISCHEMIA; YOUNG ADULT;

EID: 84896521499     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23774     Document Type: Article

References (33)

1. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 data report. Am J Transplant 2012; 12 (suppl 1): 1-156.
2. Busuttil RW, Tanaka K,. The utility of marginal donors in liver transplantation. Liver Transpl 2003; 9: 651-663.
3. Nadig SN, Bratton CF, Karp SJ,. Marginal donors in liver transplantation: expanding the donor pool. J Surg Educ 2007; 64: 46-50.
4. Fábrega E, García-Suarez C, Guerra A, Orive A, Casafont F, Crespo J, Pons-Romero F,. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 2003; 9: 916-920.
5. Saab S, Chang AJ, Comulada S, Geevarghese SK, Anselmo RD, Durazo F, et al. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl 2003; 9: 1053-1061.
6. Cholongitas E, Papatheodoridis GV, Burroughs AK,. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52: 272-279.
7. González-Peralta RP, Andres JM, Tung FY, Fang JW, Brunson ME, Davis GL, Lau JY,. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus-negative recipient. Transplantation 1994; 58: 114-116.
8. Franchello A, Ghisetti V, Marzano A, Romagnoli R, Salizzoni M,. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl 2005; 11: 922-928.
9. Ho JK, Harrigan PR, Sherlock CH, Steinbrecher UP, Erb SR, Mo T, et al. Utilization of a liver allograft from a hepatitis B surface antigen positive donor. Transplantation 2006; 81: 129-131.
10. Hwang S, Lee SG, Park KM, Kim KH, Ahn CS, Oh HB, et al. Five-year follow-up of a hepatitis B virus-positive recipient of hepatitis B surface antigen-positive living donor liver graft. Liver Transpl 2006; 12: 993-997.
11. Soejima Y, Shimada M, Taketomi A, Yoshizumi T, Uchiyama H, Ikegami T, et al. Successful living donor liver transplantation using a graft from a hepatitis B surface antigen-positive donor. Liver Int 2007; 27: 1282-1286.
12. Loggi E, Bihl F, Chisholm JV III, Biselli M, Bontadini A, Vitale G, et al. Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. J Hepatol 2009; 50: 625-630.
13. Jiang L, Yan L, Li B, Wen T, Zhao J, Jiang L, et al. Successful use of hepatitis B surface antigen-positive liver grafts in recipients with hepatitis B virus-related liver diseases. Liver Transpl 2011; 17: 1236-1238.
14. Jiao Z, Zhang Y, Han L, Zeng Y, Yan L,. Four-year follow-up of two chronic hepatitis B recipients of hepatitis B surface antigen-positive cadaveric liver grafts from asymptomatic carriers. Hepatol Res 2011; 41: 846-852.
15. Bahde R, Hölzen JP, Wolters HH, Schmidt HH, Bock CT, Lügering A, et al. Course of a HBsAg positive liver transplantation in a hepatitis B and D virus coinfected recipient. Ann Hepatol 2011; 10: 355-360.
16. Loggi E, Micco L, Ercolani G, Cucchetti A, Bihl FK, Grazi GL, et al. Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. J Hepatol 2012; 56: 579-585.
17. Levine GN, McCullough KP, Rodgers AM, Dickinson DM, Ashby VB, Schaubel DE,. Analytical methods and database design: implications for transplant researchers, 2005. Am J Transplant 2006; 6 (pt 2): 1228-1242.
18. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470.
19. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-790.
20. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H,. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
21. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-1333.
22. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M,. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661.
23. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-748.
24. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-910.
25. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M,. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-258.
26. Burton JR Jr, Shaw-Stiffel TA,. Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 2003; 9: 837-842.
27. Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003; 75: 1179-1186.
28. Pan JJ, Thosani N, Machicao VI, Fallon MB,. Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers. Hepatol Int 2011; 5: 635-643.
29. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR,. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420-1427.
30. Pfitzmann R, Nüssler NC, Hippler-Benscheidt M, Neuhaus R, Neuhaus P,. Long-term results after liver transplantation. Transpl Int 2008; 21: 234-246.
31. Yu L, Koepsell T, Manhart L, Ioannou G,. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl 2009; 15: 1343-1350.
32. Hanto DW,. Reliability of voluntary and compulsory databases and registries in the United States. Transplantation 2003; 75: 2162-2164.
33. Daily OP, Kauffman HM,. Quality control of the OPTN/UNOS transplant registry. Transplantation 2004; 77: 1309.